Purdue Pharma L.P. (Research & Development - New Jersey)

57 articles with Purdue Pharma L.P. (Research & Development - New Jersey)

• Prescription Drug Safety Network Doubles Student Reach During the 2019-2020 Academic Year

  8/25/2020

  80 percent of students in Purdue Pharma’s sponsored regions reported they felt prepared to avoid prescription drug misuse after completing the course

• Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Development of Over-the-Counter Opioid Overdose Reversal Medication

  6/23/2020

  Purdue Pharma L.P. and Harm Reduction Therapeutics, Inc. (HRT) announced today that Purdue will provide up to $6.5 million of additional financial support to HRT to advance its development of a low-cost, over-the-counter (OTC) naloxone nasal spray in the United States. Naloxone is an opioid antagonist rescue medication used to reverse

• Purdue Pharma Announces Agreement in Principle on Landmark Opioid Litigation Settlement

  9/16/2019

  Purdue Pharma L.P. announced that it has reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with 24 state attorneys general, analogous officials from 5 U.S. territories, the Plaintiffs’ Executive Committee in the multidistrict litigation, and co-lead counsel in the MDL.

• Purdue Pharma L.P. and the National Center for Wellness & Recovery at Oklahoma State University Announce Collaboration Around Research to Address the Opioid Addiction Crisis

  8/15/2019

  Purdue Pharma L.P. (“Purdue”) and the National Center for Wellness & Recovery (the “Center”) at Oklahoma State University today announced an innovative collaboration focused on accelerating solutions to the opioid addiction crisis.

• What Purdue Pharma L.P. Knew About a Oxycontin Ring that Pushed More than 1 Million Pills

  7/11/2016

• Purdue Pharma L.P. Announces Patent Agreement With Egalet And Acura Pharmaceuticals, Inc.

  5/23/2016

• National Sheriffs' Association And Purdue Pharma L.P. Lead Law Enforcement Training On Naloxone

  12/7/2015

• Eisai Company And Purdue Pharma L.P. Enter Worldwide Collaboration To Develop And Commercialize Lemborexant

  8/31/2015

• Purdue Pharma L.P. Launches TeamAgainstOpioidAbuse.com

  8/17/2015

• GlaxoSmithKline Joins Purdue Pharma L.P. in Adopting Apple’s ResearchKit for Drug R&D

  7/14/2015

• Depomed Announces Decision In Inter Partes Review Proceeding Against Purdue Pharma L.P. Confirming Patentability Of All Challenged Claims

  7/9/2015

• Purdue Pharma L.P. Release: Data On Long-Term Safety And Effectiveness Of Hysingla ER (hydrocodone bitartrate) Extended-Release Tablets CII Presented At American Pain Society Scientific Meeting

  5/13/2015

• Purdue Pharma L.P. Release: Abuse, Addiction, And Opioid Poisoning Results In Commercially-Insured Individuals Following Introduction Of Reformulated Oxycontin (oxycodone Hcl Extended-Release Tablets) CII

  3/23/2015

• Purdue Pharma L.P. Release: Hysingla™ ER (hydrocodone bitartrate) Extended-Release Tablets CII Now Available

  1/26/2015

• Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Could Bank $1 Billion From Mundipharma AG, Purdue Pharma L.P. Pain Pact

  1/12/2015

• FDA Approves Purdue Pharma L.P.’s Hard-to-Abuse Narcotic Painkiller

  7/28/2014

• Purdue Pharma L.P., A Leading Pharmaceutical Company Extends Its Infrastructure Transformation Contract With HCL Technologies

  6/18/2014

• Purdue Pharma L.P. Submits NDA For Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated To Incorporate Abuse-Deterrent Properties

  4/30/2014

• Zogenix, Inc. Falls As Rival Purdue Pharma L.P. Announces Positive Phase 3 Trial Of Abuse-Resistant Pill

  3/12/2014

• Purdue Pharma L.P. Names Mark Timney President And Chief Executive Officer

  1/27/2014